Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis Meeting Abstract
| Authors: | Peters, S.; Ramalingam, S. S.; Paz-Ares, L.; Bernabe Caro, R.; Zurawski, B.; Kim, S. W.; Alexandru, A.; Lupinacci, L.; de la Mora Jimenez, E.; Sakai, H.; Albert, I.; Vergnenegre, A.; Reck, M.; Borghaei, H.; Brahmer, J. R.; O'Byrne, K. J.; Geese, W. J.; Bhagavatheeswaran, P.; Nathan, F. E.; Hellmann, M. D. |
| Abstract Title: | Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz394.075 |
| Language: | English |
| ACCESSION: | WOS:000491295500128 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz394.075 |
| Notes: | Meeting Abstract: LBA4_PR -- Appears on pages v913-v914 of the abstract book -- Source: Wos |
